• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2022 - 2023年加拿大安大略省呼吸道合胞病毒实时医院监测系统评估

Evaluation of a real-time hospital surveillance system for respiratory syncytial virus, Ontario, Canada, 2022-2023.

作者信息

Murti Michelle, Sarnocinska Ania, Alavinejad Mahnaz, Kerem Aidin, Malikov Kamil, Brown Kevin, Fitzpatrick Tiffany, Hillmer Michael

机构信息

Ministry of Health, Toronto, ON.

Dalla Lana School of Public Health, University of Toronto, Toronto, ON.

出版信息

Can Commun Dis Rep. 2025 Aug 28;51(8):297-302. doi: 10.14745/ccdr.v51i08a02. eCollection 2025 Aug.

DOI:10.14745/ccdr.v51i08a02
PMID:40909213
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12407583/
Abstract

BACKGROUND

Respiratory syncytial virus (RSV) surged in the 2022-2023 respiratory season after low activity during the pandemic. To monitor the RSV season in real time and support healthcare planning, Ontario introduced daily hospital bed census reporting of RSV hospitalizations by age group (0-17, 18-64, 65 years and older).

OBJECTIVES

To assess the completeness and quality of the newly introduced real-time surveillance compared to end-of-season ICD-10 coded hospitalization discharge abstract data (DAD) from November 22, 2022, to March 31, 2023.

METHODS

Respiratory syncytial virus hospitalizations from both data sources were compared to RSV laboratory positivity to assess concordance with overall RSV activity. A longitudinal comparison by age group was assessed by time-lagged cross-correlation of the daily submission data versus DAD data, including cross correlation coefficients for each time lag, confidence bound and the highest correlation value.

RESULTS

Both data sources followed trends in RSV positivity. Data by age groups showed an early peak of paediatric admissions followed by a peak in adult and older adult hospitalizations. Daily surveillance consistently underestimated hospitalizations with a peak of 430 beds by DAD on January 7, 2023, versus 322 beds (75%) for daily reporting on the same day. The maximum correlation coefficient values were 0.67 (all ages), 0.57 (0-17 years), 0.66 (18-64 years) and 0.63 (65 years and older).

CONCLUSION

Implementation of daily hospital reporting provided accurate trending in RSV hospitalizations by age group to inform within season healthcare and public health planning.

摘要

背景

呼吸道合胞病毒(RSV)在疫情期间活动较低后,于2022 - 2023年呼吸道季节激增。为了实时监测RSV季节并支持医疗规划,安大略省引入了按年龄组(0 - 17岁、18 - 64岁、65岁及以上)每日报告RSV住院患者的医院病床普查数据。

目的

评估与2022年11月22日至2023年3月31日季末国际疾病分类第十版(ICD - 10)编码的住院出院摘要数据(DAD)相比,新引入的实时监测的完整性和质量。

方法

将两个数据源的呼吸道合胞病毒住院数据与RSV实验室阳性结果进行比较,以评估与总体RSV活动的一致性。通过每日提交数据与DAD数据的时间滞后互相关分析按年龄组进行纵向比较,包括每个时间滞后的互相关系数、置信区间和最高相关值。

结果

两个数据源均遵循RSV阳性趋势。按年龄组的数据显示,儿科入院有一个早期高峰,随后是成人和老年住院患者的高峰。每日监测始终低估了住院人数,2023年1月7日DAD显示的住院高峰为430张床位,而当日每日报告为322张床位(75%)。最大相关系数值分别为0.67(所有年龄)、0.57(0 - 17岁)、0.66(18 - 64岁)和0.63(65岁及以上)。

结论

每日医院报告的实施提供了按年龄组划分的RSV住院患者的准确趋势,为季节内的医疗保健和公共卫生规划提供信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0788/12407583/1f3d533c9745/510802-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0788/12407583/61b0907a6ddb/510802-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0788/12407583/4bc24b9f0f18/510802-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0788/12407583/7adb2d3a61ba/510802-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0788/12407583/1f3d533c9745/510802-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0788/12407583/61b0907a6ddb/510802-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0788/12407583/4bc24b9f0f18/510802-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0788/12407583/7adb2d3a61ba/510802-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0788/12407583/1f3d533c9745/510802-f4.jpg

相似文献

1
Evaluation of a real-time hospital surveillance system for respiratory syncytial virus, Ontario, Canada, 2022-2023.2022 - 2023年加拿大安大略省呼吸道合胞病毒实时医院监测系统评估
Can Commun Dis Rep. 2025 Aug 28;51(8):297-302. doi: 10.14745/ccdr.v51i08a02. eCollection 2025 Aug.
2
Burden of Respiratory Syncytial Virus-Associated Hospitalizations in US Adults, October 2016 to September 2023.美国成年人呼吸道合胞病毒相关住院负担,2016 年 10 月至 2023 年 9 月。
JAMA Netw Open. 2024 Nov 4;7(11):e2444756. doi: 10.1001/jamanetworkopen.2024.44756.
3
Respiratory syncytial virus-associated hospitalizations among children: an Italian retrospective observational study.呼吸道合胞病毒相关儿童住院治疗:意大利回顾性观察研究。
Ital J Pediatr. 2024 Mar 7;50(1):45. doi: 10.1186/s13052-024-01617-w.
4
Scenario Projections of Respiratory Syncytial Virus Hospitalizations Averted Due to New Immunizations.因新型免疫接种避免的呼吸道合胞病毒住院病例的情景预测。
JAMA Netw Open. 2025 Jun 2;8(6):e2514622. doi: 10.1001/jamanetworkopen.2025.14622.
5
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.对帕利珠单抗用于呼吸道合胞病毒免疫预防给药依从性的系统评价。
J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. doi: 10.18553/jmcp.2010.16.1.46.
6
Respiratory syncytial virus-attributable hospitalizations among adults in high- and middle-income countries: application of the Global Burden of Disease framework.中高收入国家成人中呼吸道合胞病毒所致住院情况:全球疾病负担框架的应用
EClinicalMedicine. 2025 Jun 16;85:103292. doi: 10.1016/j.eclinm.2025.103292. eCollection 2025 Jul.
7
Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23 and beyond: protocol for a pragmatic sub-study.调整新冠病毒研究基础设施,以便在2022/23年冬季及以后在英国医护人员中同时收集流感病毒、呼吸道合胞病毒以及严重急性呼吸综合征冠状病毒2:一项务实子研究的方案
NIHR Open Res. 2024 Nov 5;4:1. doi: 10.3310/nihropenres.13517.2. eCollection 2024.
8
Efficacy, safety, and immunogenicity of the AS01-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.AS01佐剂呼吸道合胞病毒预融合F蛋白疫苗(RSVPreF3 OA)在三个呼吸道合胞病毒流行季中对老年人的有效性、安全性和免疫原性(AReSVi-006):一项多中心、随机、观察者盲法、安慰剂对照的3期试验
Lancet Respir Med. 2025 Jun;13(6):517-529. doi: 10.1016/S2213-2600(25)00048-7. Epub 2025 Apr 14.
9
Shifts in Influenza and Respiratory Syncytial Virus Infection Patterns in Korea After the COVID-19 Pandemic Resulting From Immunity Debt: Retrospective Observational Study.新冠疫情后韩国因免疫债导致的流感和呼吸道合胞病毒感染模式转变:回顾性观察研究
JMIR Public Health Surveill. 2025 Jul 23;11:e68058. doi: 10.2196/68058.
10
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.用于降低儿童呼吸道合胞病毒感染风险的单克隆抗体。
Cochrane Database Syst Rev. 2013 Apr 30(4):CD006602. doi: 10.1002/14651858.CD006602.pub4.

本文引用的文献

1
Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic.儿科呼吸道合胞病毒相关住院治疗在 COVID-19 大流行之前和期间。
JAMA Netw Open. 2023 Oct 2;6(10):e2336863. doi: 10.1001/jamanetworkopen.2023.36863.
2
Estimating the Incidence of First RSV Hospitalization in Children Born in Ontario, Canada.估算在加拿大安大略省出生的儿童首次因 RSV 住院的发生率。
J Pediatric Infect Dis Soc. 2023 Jul 31;12(7):421-430. doi: 10.1093/jpids/piad045.
3
Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis.
高收入国家 60 岁及以上成年人呼吸道合胞病毒疾病负担:系统文献回顾和荟萃分析。
Influenza Other Respir Viruses. 2023 Jan;17(1):e13031. doi: 10.1111/irv.13031. Epub 2022 Nov 11.
4
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.2019 年全球、区域和国家因呼吸道合胞病毒导致 5 岁以下儿童急性下呼吸道感染的疾病负担估计:系统分析。
Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.